Inflammation and sepsis: Past, present, and the future

Journal of Burn Care and Research

Volumn 28, Issue 4, 2007, Pages 566-571

  Shankar, Ravi ^a   Melstrom Jr , Kurt A ^a   Gamelli, Richard L ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; LINEZOLID;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; ASSISTED VENTILATION; BLOOD CLOTTING; BURN INFECTION; CONFERENCE PAPER; CYTOKINE RELEASE; ENERGY CONSUMPTION; FLUID RESUSCITATION; HUMAN; IMMUNE RESPONSE; IMMUNODETECTION; INJURY SEVERITY; INNATE IMMUNITY; METABOLIC DISORDER; MULTIPLE ORGAN FAILURE; PATIENT CARE; PROTEOMICS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BURNS; CRITICAL ILLNESS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; RISK FACTORS; SEPSIS;

EID: 34447498464     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0B013E318093DF16     Document Type: Conference Paper

References (39)

1. Schwacha MG. Macrophages and post-burn immune dysfunction. Burns 2003;29:1-14.
2. Sparkes BG. Immunological responses to thermal injury. Burns 1997;23:106-13.
3. Williams IR, Kupper TS. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci 1996;58:1485-507.
4. DiPietro LA. Wound healing: the role of the macrophage and other immune cells. Shock 1995;4:233-40.
5. Martin P, Leibovich SJ. Inflammatory cells during wound repair: the good, the bad and the ugly. Trends Cell Biol 2005;15:599-607.
6. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by beta-blockade after severe burns. N Engl J Med 2001;345:1223-9.
7. Takahashi H, Tsuda Y, Takeuchi D, et al. Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 2004;32:1879-85.
8. Nystrom PO. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother 1998;41(Suppl A):1-7.
9. Smith JW, Gamelli RL, Jones SB, et al. Immunologic responses to critical injury and sepsis. J Intensive Care Med 2006;21:160-72.
10. Bone RC. A personal experience with SIRS and MODS. Crit Care Med 1996;24:1417-8.
11. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996;24:1125-8.
12. Bone RC. The sepsis syndrome. Definition and general approach to management. Clin Chest Med 1996;17:175-81.
13. Faist E. The mechanisms of host defense dysfunction following shock and trauma. Curr Top Microbiol Immunol 1996;216:259-74.
14. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000;343:37-49.
15. Oberholzer A, Oberholzer C, Moldawer LL. Sepsis syndromes: understanding the role of innate and acquired immunity. Shock 2001;16:83-96.
16. Goldmann O, Chhatwal GS, Medina E. Contribution of natural killer cells to the pathogenesis of septic shock induced by Streptococcus pyogenes in mice. J Infect Dis 2005;191:1280-6.
17. Fujiwara N, Kobayashi K. Macrophages in inflammation. Curr Drug Targets Inflamm Allergy 2005;4:281-6.
18. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006;311:17-58.
19. Jutras I, Desjardins M. Phagocytosis: at the crossroads of innate and adaptive immunity. Annu Rev Cell Dev Biol 2005;21:511-27.
20. Dunne JR, Malone DL, Tracy JK, et al. Allogenic blood transfusion in the first 24 hours after trauma is associated with increased systemic inflammatory response syndrome (SIRS) and death. Surg Infect 2004;5:395-404.
21. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998;351:929-33.
22. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355.
23. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999;25:556-66.
24. von Bubnoff A. Seeking new antibiotics in nature's backyard. Cell 2006;127:867-9.
25. Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
26. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003;348:138-50.
27. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005;437:1032-7.
28. Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A 2005;102:4801-6.
29. Chung TP, Laramie JM, Meyer DJ, et al. Molecular diagnostics in sepsis: from bedside to bench. J Am Coll Surg 2006;203:585-98.
30. Wilson JW, Schurr MJ, LeBlanc CL, et al. Mechanisms of bacterial pathogenicity. Postgrad Med J 2002;78:216-24.
31. Melstrom KA, Jr., Smith JW, Gamelli RL, et al. New perspectives for a new century: implications of pathogen responses for the future of antimicrobial therapy. J Burn Care Res 2006;27:251-64.
32. Winsor GL, Lo R, Sui SJ, et al. Pseudomonas aeruginosa Genome Database and PseudoCAP: facilitating community-based, continually updated, genome annotation. Nucleic Acids Res 2005;33:D338-43.
33. Bassler BL, Losick R. Bacterially speaking. Cell 2006;125:237-46.
34. Navarro L, Alto NM, Dixon JE. Functions of the Yersinia effector proteins in inhibiting host immune responses. Curr Opin Microbiol 2005;8:21-7.
35. Sebbane F, Lemaitre N, Sturdevant DE, et al. Adaptive response of Yersinia pestis to extracellular effectors of innate immunity during bubonic plague. Proc Natl Acad Sci U S A 2006;103:11766-71.
36. Ochsner UA, Vasil ML, Alsabbagh E, et al. Role of the Pseudomonas aeruginosa oxyR-recG operon in oxidative stress defense and DNA repair: OxyR-dependent regulation of katB-ankB, ahpB, and ahpC-ahpF. J Bacteriol 2000;182:4533-44.
37. Melstrom KA, Muthu K, He LK, et al. OxyR gene expression of Pseudomonas aeruginosa regulates bone marrow dendritic cell differentiation and function after burn sepsis. J Am Coll Surg 2006;203:S34.
38. Gonzalez JE, Keshavan ND. Messing with bacterial quorum sensing. Microbiol Mol Biol Rev 2006;70:859-75.
39. Smith RS, Iglewski BH. Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J Clin Invest 2003;112:1460-5.